Related Experiment Video
Updated: Jun 4, 2026

Identification of Sleeping Beauty Transposon Insertions in Solid Tumors using Linker-mediated PCR
Published on: February 1, 2013
A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing
Ryuya Murai1, Yoko Yoshida1, Teruyuki Muraguchi1
1Department of Molecular Oncology, Kyoto University Graduate School of Medicine, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan.
Abstract:
The membrane-anchored matrix metalloproteinase-regulator RECK is often downregulated in various types of cancers; the levels of residual RECK in resected tumors often correlate with better prognosis. Forced expression of RECK in cancer cells suppresses tumor angiogenesis, invasion, and metastasis in xenograft models. RECK is therefore a promising marker for benignancy and a potential effector in cancer therapy. We established a cell line containing two transgene systems: (1) the secreted alkaline phosphatase (SEAP) gene fused to Reck promoter and (2) the HRAS(12V) oncogene driven by the Tet-off promoter system. This cell line exhibits transformed phenotype in regular medium and flat morphology with increased SEAP activity in the presence of doxycycline, allowing the assessment of RECK-inducing activity of chemicals in the contexts of both transformed and untransformed cells. Our pilot experiments with 880 known bioactive compounds detected 34 compounds that activate RECK promoter; among these, 10 were authentic anticancer drugs. Four selected compounds up-regulated endogenous RECK protein in several human cancer cell lines. The top-ranking compound, disulfiram, strongly suppressed spontaneous lung-metastasis of human fibrosarcoma cells in nude mice. Our data demonstrate the value of this screen in discovering effective cancer therapeutics.
Insights
The RECK protein, a cancer suppressor, can be reactivated by certain compounds. Disulfiram, an identified compound, significantly reduced lung metastasis in preclinical cancer models.
Area of Science:
- Oncology
- Molecular Biology
Background:
- RECK (Reversion-Inducing Cysteine-Rich Protein-rich protein) is a membrane-anchored metalloproteinase regulator frequently downregulated in cancers.
- Low RECK levels in tumors correlate with poor prognosis, while its forced expression inhibits cancer progression in models.
- RECK is a potential biomarker for benignancy and a therapeutic target in cancer treatment.
Purpose of the Study:
- To develop and validate a screening system for identifying compounds that can restore RECK expression in cancer cells.
- To evaluate the therapeutic potential of RECK-inducing compounds in preclinical cancer models.
Main Methods:
- Established a dual-transgene cell line with a RECK promoter-SEAP reporter and a Tet-off regulated HRAS(12V) oncogene.
- Screened 880 bioactive compounds for RECK promoter activation in both transformed and untransformed cells.
- Validated selected compounds for their ability to upregulate endogenous RECK protein and suppress metastasis in vivo.
Main Results:
- Identified 34 compounds activating the RECK promoter, including 10 known anticancer drugs.
- Four compounds demonstrated upregulation of endogenous RECK protein in human cancer cell lines.
- Disulfiram, a top-ranked compound, significantly suppressed spontaneous lung metastasis of fibrosarcoma cells in mice.
Conclusions:
- The developed cell line is effective for screening RECK-inducing compounds.
- Disulfiram shows significant preclinical efficacy in suppressing cancer metastasis.
- This screening approach holds promise for discovering novel cancer therapeutics targeting RECK.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mitogens and the Cell Cycle
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

